Friström B, Nilsson S E
Department of Ophthalmology, University of Linköping, Sweden.
Br J Ophthalmol. 1997 Oct;81(10):867-70. doi: 10.1136/bjo.81.10.867.
To compare the intraocular pressure (IOP) reducing effect of latanoprost 0.005% and 0.001%.
Twenty four patients with glaucoma or ocular hypertension were randomised into two groups. Twelve patients (group 1) were given latanoprost 0.005% once daily for 4 weeks and then latanoprost 0.001% once daily for the following 4 weeks. Twelve patients (group 2) were given latanoprost 0.001% once daily for 4 weeks and then latanoprost 0.005% for the following 4 weeks.
There was a significant IOP reduction from baseline in both groups on day 28 as well as on day 56. When the results from both groups were used for calculations, the mean IOP reduction from baseline after 4 weeks of treatment with latanoprost 0.005% (day 28 or 56) was 9.6 (SD 3.3) mm Hg (35.0%). After 4 weeks of treatment with latanoprost 0.001%, the IOP reduction (day 28 or 56) was 7.6 (3.4) mm Hg (27.7%). The difference in IOP reduction between the two concentrations was 2.0 (2.3) mm Hg (p < 0.001).
Latanoprost 0.005% was more effective than latanoprost 0.001% in reducing IOP. Even the lower concentration was surprisingly effective, and potentially may be of importance for use in clinical practice. Furthermore, it is at present unknown whether the increase in iris pigmentation seen in certain patients treated with latanoprost 0.005% is dose dependent and might be less pronounced with latanoprost 0.001%. Long term studies with a larger number of patients are required in order to answer this question.
比较0.005%和0.001%拉坦前列素降低眼压的效果。
24例青光眼或高眼压症患者被随机分为两组。12例患者(第1组)每天一次给予0.005%拉坦前列素,持续4周,随后4周每天一次给予0.001%拉坦前列素。12例患者(第2组)每天一次给予0.001%拉坦前列素,持续4周,随后4周给予0.005%拉坦前列素。
两组在第28天和第56天时眼压均较基线水平有显著降低。当将两组结果用于计算时,用0.005%拉坦前列素治疗4周后(第28天或56天),眼压较基线水平平均降低9.6(标准差3.3)mmHg(35.0%)。用0.001%拉坦前列素治疗4周后,眼压降低(第28天或56天)为7.6(3.4)mmHg(27.7%)。两种浓度的拉坦前列素在眼压降低方面的差异为2.0(2.3)mmHg(p<0.001)。
0.005%拉坦前列素在降低眼压方面比0.001%拉坦前列素更有效。即使是较低浓度也有惊人的效果,并且在临床实践中可能具有潜在的重要性。此外,目前尚不清楚某些接受0.005%拉坦前列素治疗的患者中出现的虹膜色素沉着增加是否与剂量有关,以及0.001%拉坦前列素是否会不那么明显。需要对更多患者进行长期研究以回答这个问题。